{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:40:01Z","timestamp":1793338801803,"version":"4.5.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonalcoholic fatty liver disease (NAFLD) is a metabolic disorder characterized by hepatic steatosis and inflammation in individuals with no significant alcohol consumption history. Predominantly affecting middle-aged and elderly populations, particularly those with obesity or metabolic syndrome, this condition represents a spectrum ranging from benign fatty accumulation to progressive liver damage. In advanced stages, NAFLD may progress to cirrhosis and hepatocellular carcinoma. This study systematically examines the global incidence patterns and epidemiological characteristics of NAFLD in older adults(&gt;60 years), while establishing predictive models for its future disease burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data on NAFLD in the Elderly(&gt;60 years), from 1990 to 2021, was obtained from the Global Burden of Disease (GBD) study, encompassing 204 countries and territories. This dataset includes incidence rates of NAFLD. The Joinpoint regression model was utilized to detect turning points in the epidemiological trends of NAFLD, and decomposition analysis was performed to analyze the factors influencing these trends. To evaluate potential health disparities related to NAFLD, the Slope Index and Concentration Index were calculated. Additionally, the Norpred and Bayesian age-period-cohort (BAPC) models were employed to forecast future incidence rates of NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 1990, the global NAFLD incidence in the elderly was 2819125(3972309\u2009\u00b1\u20091807520), with an ASIR of 568.46(803.33\u2009\u00b1\u2009364.10). The global NAFLD prevalence in the elderly was 132549345(166820867\u2009\u00b1\u2009102941502), with an ASPR of 27284.94(34321.92\u2009\u00b1\u200921200.69). The global NAFLD deaths in the elderly were 27864(45975\u2009\u00b1\u200915898), with an age-standardized death rate of 6.20(10.18\u2009\u00b1\u20093.55). The global NAFLD DALYs in the elderly were 559945(931920\u2009\u00b1\u2009319045), with an age-standardized DALYs rate of 116.78(193.49\u2009\u00b1\u200966.73). In 2021, the global NAFLD incidence in the elderly was 7,012,128 (9,896,736\u2009\u00b1\u20094,480,162), with an ASIR of 636.90 (900.15\u2009\u00b1\u2009406.76). The global NAFLD prevalence in the elderly was 366,363,498 (454,385,769\u2009\u00b1\u2009287,891,088), with an ASPR of 33,576.22 (41,647.44\u2009\u00b1\u200926,372.13). The global NAFLD deaths in the elderly were 63,313 (99,891\u2009\u00b1\u200937,267), with an age-standardized death rate of 5.95 (9.39\u2009\u00b1\u20093.50). The global NAFLD DALYs in the elderly were 1,238,927 (1,973,042\u2009\u00b1\u2009729,228), with an age-standardized DALYs rate of 113.95 (181.50\u2009\u00b1\u200966.91). From 1990 to 2021, the AAPC of ASIR for NAFLD in the elderly globally was 0.37(0.36 to 0.38), with a p-value\u2009&lt;\u20090.05. The AAPC of ASPR for NAFLD in the elderly globally was 0.67(0.65 to 0.68), with a p-value\u2009&lt;\u20090.05. The AAPC of age-standardized deaths rate for NAFLD in the elderly globally was \u22120.13(\u22120.16 to \u22120.1), with a p-value\u2009&lt;\u20090.05. The AAPC of age-standardized DALYs rate for NAFLD in the elderly globally was \u22120.05(\u22120.07 to \u22120.02), with a p-value\u2009&lt;\u20090.05. The decomposition analysis results indicate that population growth is the primary driver of increased disease burden in older NAFLD patients. It is expected that in the future, the disease burden of NAFLD in elderly people worldwide will continue to rise.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Over the past three decades, the annual age-standardized incidence rate and total number of cases of NAFLD, including cirrhosis, have increased among the elderly population, irrespective of gender. This upward trend is consistent across all SDI regions. Furthermore, future projections indicate that both the annual age-standardized incidence rate and the case numbers of NAFLD, including cirrhosis, in the elderly are likely to continue rising.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0325961","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T13:31:11Z","timestamp":1750858271000},"page":"e0325961","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["The global impact of non-alcoholic fatty liver disease (including cirrhosis) in the elderly from 1990 to 2021 and future projections of disease burden"],"prefix":"10.1371","volume":"20","author":[{"given":"Siying","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weitao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4017-0088","authenticated-orcid":true,"given":"Taiyong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"2","key":"pone.0325961.ref001","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41575-020-00406-0","article-title":"Nonalcoholic fatty liver disease: another leap forward","volume":"18","author":"MF Abdelmalek","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"pone.0325961.ref002","doi-asserted-by":"crossref","first-page":"118468","DOI":"10.1016\/j.jep.2024.118468","article-title":"Pueraria lobata antioxidant extract ameliorates non-alcoholic fatty liver by altering hepatic fat accumulation and oxidative stress","volume":"333","author":"H Dong","year":"2024","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"pone.0325961.ref003","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.32655","article-title":"Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis","volume":"77","author":"D Chang","year":"2023","journal-title":"Hepatology"},{"issue":"7","key":"pone.0325961.ref004","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2174\/138955709788452676","article-title":"Diagnosis and therapy of autoimmune hepatitis","volume":"9","author":"A Granito","year":"2009","journal-title":"Mini Rev Med Chem"},{"issue":"5","key":"pone.0325961.ref005","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/apt.14910","article-title":"Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors","volume":"48","author":"F Tovoli","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0325961.ref006","first-page":"101602","article-title":"Sudden cardiac death associated with fatty liver disease","volume":"56","author":"J Vo","year":"2025","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"8","key":"pone.0325961.ref007","article-title":"Serum thrombospondin-2 levels are closely associated with the severity of metabolic syndrome and metabolic associated fatty liver disease","volume":"107","author":"X Wu","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0325961.ref008","doi-asserted-by":"crossref","first-page":"112334","DOI":"10.1016\/j.exger.2023.112334","article-title":"Old age as a risk factor for liver diseases: modern therapeutic approaches","volume":"184","author":"M Georgieva","year":"2023","journal-title":"Exp Gerontol"},{"issue":"3","key":"pone.0325961.ref009","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/nu12030622","article-title":"Physical activity and diet shape the immune system during aging","volume":"12","author":"C Weyh","year":"2020","journal-title":"Nutrients"},{"issue":"4","key":"pone.0325961.ref010","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","volume":"67","author":"JG Fan","year":"2017","journal-title":"J Hepatol"},{"issue":"7","key":"pone.0325961.ref011","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/oby.23779","article-title":"Age- and sex-specific changes in visceral fat mass throughout the life-span","volume":"31","author":"RB Baarts","year":"2023","journal-title":"Obesity"},{"issue":"4","key":"pone.0325961.ref012","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"ZM Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0325961.ref013","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jdi.13756","article-title":"Non-alcoholic fatty liver disease and type\u20092 diabetes: An update","volume":"13","author":"C-H Lee","year":"2022","journal-title":"J Diabetes Investig"},{"issue":"8","key":"pone.0325961.ref014","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3390\/cells10082034","article-title":"NAFLD-related hepatocarcinoma: the malignant side of metabolic syndrome","volume":"10","author":"A Michelotti","year":"2021","journal-title":"Cells"},{"issue":"2","key":"pone.0325961.ref015","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"11","key":"pone.0325961.ref016","first-page":"2473","article-title":"Trends and projections of mortality attributed to occupational neoplasms and occupational tracheal, bronchus, and lung cancer in the world, G7 countries and Turkey","volume":"53","author":"EN Y\u0131ld\u0131r\u0131m-Ozturk","year":"2024","journal-title":"Iran J Public Health"},{"issue":"11","key":"pone.0325961.ref017","article-title":"Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019","volume":"6","author":"Global Burden of Disease Bladder Cancer Collaborators","year":"2021","journal-title":"BMJ Glob Health"},{"issue":"9","key":"pone.0325961.ref018","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S2213-2600(21)00164-8","article-title":"Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","author":"GBD 2019 Respiratory Tract Cancers Collaborators","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"pone.0325961.ref019","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000013115","article-title":"Global, regional, and national burden of nonalcoholic fatty liver disease including cirrhosis, 1990-2019","volume":"98","author":"Q Ding","year":"2022","journal-title":"Neurology"},{"key":"pone.0325961.ref020","doi-asserted-by":"crossref","first-page":"101936","DOI":"10.1016\/j.eclinm.2023.101936","article-title":"Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019","volume":"59","author":"GBD 2019 Chronic Respiratory Diseases Collaborators","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"pone.0325961.ref021","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1186\/s12889-023-16295-2","article-title":"Global incidence, prevalence and disease burden of silicosis: 30 years\u2019 overview and forecasted trends","volume":"23","author":"X Liu","year":"2023","journal-title":"BMC Public Health"},{"key":"pone.0325961.ref022","doi-asserted-by":"crossref","DOI":"10.1590\/1980-549720230037","article-title":"Temporal and spatial distribution of polio vaccine coverage in Brazil between 1997 and 2021","volume":"26","author":"NS Maciel","year":"2023","journal-title":"Rev Bras Epidemiol"},{"issue":"2","key":"pone.0325961.ref023","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators","year":"2022","journal-title":"Lancet Public Health"},{"key":"pone.0325961.ref024","doi-asserted-by":"crossref","first-page":"102124","DOI":"10.1016\/j.arr.2023.102124","article-title":"Global, regional, and national prevalence of hearing loss from 1990 to 2019: a trend and health inequality analyses based on the Global Burden of Disease Study 2019","volume":"92","author":"C-Y Jiang","year":"2023","journal-title":"Ageing Res Rev"},{"key":"pone.0325961.ref025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.puhe.2022.04.015","article-title":"Global disease burden of COPD from 1990 to 2019 and prediction of future disease burden trend in China","volume":"208","author":"W Hu","year":"2022","journal-title":"Public Health"},{"key":"pone.0325961.ref026","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jot.2024.03.002","article-title":"Global, regional, national trends of femur fracture and machine learning prediction: comprehensive findings and questions from global burden of disease 1992-2019","volume":"46","author":"J Wu","year":"2024","journal-title":"J Orthop Translat"},{"issue":"5","key":"pone.0325961.ref027","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","article-title":"Gut microbial metabolites in obesity, NAFLD and T2DM","volume":"15","author":"EE Canfora","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"pone.0325961.ref028","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"L Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"pone.0325961.ref029","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jare.2022.08.006","article-title":"ANGPTL8 accelerates liver fibrosis mediated by HFD-induced inflammatory activity via LILRB2\/ERK signaling pathways","volume":"47","author":"Z Zhang","year":"2023","journal-title":"J Adv Res"},{"issue":"5","key":"pone.0325961.ref030","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1210\/er.2019-00034","article-title":"The liver as an endocrine organ-linking NAFLD and insulin resistance","volume":"40","author":"MJ Watt","year":"2019","journal-title":"Endocr Rev"},{"issue":"4","key":"pone.0325961.ref031","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis","volume":"75","author":"EA Selvaraj","year":"2021","journal-title":"J Hepatol"},{"key":"pone.0325961.ref032","article-title":"GLP-1 receptor agonists in NAFLD","author":"J-M Petit","year":"2017","journal-title":"Diabetes Metab"},{"issue":"4","key":"pone.0325961.ref033","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"G Targher","year":"2024","journal-title":"Gut"},{"issue":"1","key":"pone.0325961.ref034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Z Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"pone.0325961.ref035","doi-asserted-by":"crossref","first-page":"104714","DOI":"10.1016\/j.ebiom.2023.104714","article-title":"Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases","volume":"94","author":"B Dewidar","year":"2023","journal-title":"EBioMedicine"},{"issue":"9","key":"pone.0325961.ref036","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"K Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10471","key":"pone.0325961.ref037","first-page":"2543","article-title":"Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"404","author":"Global Nutrition Target Collaborators","year":"2025","journal-title":"Lancet"},{"issue":"5","key":"pone.0325961.ref038","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2021.07.025","article-title":"Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention","volume":"75","author":"NF Lange","year":"2021","journal-title":"J Hepatol"},{"key":"pone.0325961.ref039","doi-asserted-by":"crossref","first-page":"123615","DOI":"10.1016\/j.envpol.2024.123615","article-title":"Exposure to per- and polyfluoroalkyl substance and metabolic syndrome: a nationally representative cross-sectional study from NHANES, 2003-2018","volume":"346","author":"M Wu","year":"2024","journal-title":"Environ Pollut"},{"issue":"1","key":"pone.0325961.ref040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-023-02793-y","article-title":"Associations between an inflammatory diet index and severe non-alcoholic fatty liver disease: a prospective study of 171,544 UK Biobank participants","volume":"21","author":"F Petermann-Rocha","year":"2023","journal-title":"BMC Med"},{"issue":"3","key":"pone.0325961.ref041","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ajcnut.2023.11.013","article-title":"Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial","volume":"119","author":"YC Chooi","year":"2024","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"pone.0325961.ref042","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/j.2040-4603.2012.tb00425.x","article-title":"Lack of exercise is a major cause of chronic diseases","volume":"2","author":"FW Booth","year":"2012","journal-title":"Compr Physiol"},{"issue":"2","key":"pone.0325961.ref043","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1037\/amp0001113","article-title":"Health inequities and social determinants of health in refugee and immigrant communities","volume":"78","author":"F Rami","year":"2023","journal-title":"Am Psychol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325961","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T13:31:23Z","timestamp":1750858283000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325961"}},"subtitle":[],"editor":[{"given":"Thien Tan Tri Tai","family":"Truyen,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0325961","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]}}}